Market Research Logo

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

Summary


RSV infects the lungs and breathing passages. Symptoms include cough, stuffy or runny nose, mild sore throat, earache and fever. There are 127 products in development for RSV infections and key companies operating in this pipeline space include Johnson & Johnson, MedImmune and ReViral.

HPIV-3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough runny nose, croup, bronchiolitis, wheezing and sore throat. There are five products in development for HPIV-3 infections and companies operating in this pipeline space include Ansun Biopharma and Amarillo Biosciences.

Molecular targets present in the RSV and HPIV-3 pipeline landscapes include exo alpha sialidase and fatty acid synthase.

This report “Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3). It comprehensively documents therapeutics under development for RSV and HPIV-3 infections, and features dormant and discontinued products.

Scope

  • Which companies are the most active within the pipeline for RSV and HPIV-3 infections?
  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • Executive Summary
  • Introduction
    • GBI Research Report Coverage
    • Respiratory Syncytial Virus (RSV) Infections – Overview
    • Human Parainfluenza Virus 3 Infections – Overview
  • Therapeutics Development
    • Respiratory Syncytial Virus (RSV) Infections
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections
        • Table Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections
        • Table Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections
      • Pipeline by Universities/Institutes
        • Table Figure 3: Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections
        • Table Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections
      • Products under Development by Companies
        • Table Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections
    • Human Parainfluenza Virus 3 Infections
      • Pipeline Overview
        • Table Figure 4: Number of Products under Development for Human Parainfluenza Virus 3 Infections
        • Table Number of Products under Development for Human Parainfluenza Virus 3 Infections
      • Pipeline by Companies
        • Table Figure 5: Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections
        • Table Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections
      • Products under Development by Companies
        • Table Products under Development by Companies, Human Parainfluenza Virus 3 Infections
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections
  • Therapeutics Assessment
    • Respiratory Syncytial Virus (RSV) Infections
      • Assessment by Target
        • Table Figure 6: Number of Products by Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections
        • Table Figure 7: Number of Products by Stage and Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections
        • Table Number of Products by Stage and Target, Respiratory Syncytial Virus (RSV) Infections
      • Assessment by Mechanism of Action
        • Table Figure 8: Number of Products by Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections
        • Table Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections
        • Table Number of Products by Stage and Mechanism of Action, Respiratory Syncytial Virus (RSV) Infections
      • Assessment by Route of Administration
        • Table Figure 10: Number of Products by Routes of Administration, Respiratory Syncytial Virus (RSV) Infections
        • Table Figure 11: Number of Products by Stage and Routes of Administration, Respiratory Syncytial Virus (RSV) Infections
        • Table Number of Products by Stage and Route of Administration, Respiratory Syncytial Virus (RSV) Infections
      • Assessment by Molecule Type
        • Table Figure 12: Number of Products by Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections
        • Table Figure 13: Number of Products by Stage and Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections
        • Table Number of Products by Stage and Molecule Type, Respiratory Syncytial Virus (RSV) Infections
    • Human Parainfluenza Virus 3 Infections
      • Assessment by Target
        • Table Figure 14: Number of Products by Targets, Human Parainfluenza Virus 3 Infections
        • Table Figure 15: Number of Products by Stage and Targets, Human Parainfluenza Virus 3 Infections
        • Table Number of Products by Stage and Target, Human Parainfluenza Virus 3 Infections
      • Assessment by Mechanism of Action
        • Table Figure 16: Number of Products by Mechanism of Actions, Human Parainfluenza Virus 3 Infections
        • Table Figure 17: Number of Products by Stage and Mechanism of Actions, Human Parainfluenza Virus 3 Infections
        • Table Number of Products by Stage and Mechanism of Action, Human Parainfluenza Virus 3 Infections
      • Assessment by Route of Administration
        • Table Figure 18: Number of Products by Top 10 Routes of Administration, Human Parainfluenza Virus 3 Infections
        • Table Figure 19: Number of Products by Stage and Routes of Administration, Human Parainfluenza Virus 3 Infections
        • Table Number of Products by Stage and Route of Administration, Human Parainfluenza Virus 3 Infections
      • Assessment by Molecule Type
        • Table Figure 20: Number of Products by Molecule Types, Human Parainfluenza Virus 3 Infections
        • Table Figure 21: Number of Products by Stage and Molecule Types, Human Parainfluenza Virus 3 Infections
        • Table Number of Products by Stage and Molecule Type, Human Parainfluenza Virus 3 Infections
  • Companies Involved in Therapeutics Development
    • Respiratory Syncytial Virus (RSV) Infections
      • 3-V Biosciences Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by 3-V Biosciences Inc,
      • Abivax SA
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA
      • Ablynx NV
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ablynx NV
      • ADMA Biologics Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics Inc
      • Agilvax Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Agilvax Inc
      • Amarillo Biosciences Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Amarillo Biosciences Inc
      • Anima Biotech Ltd
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Anima Biotech Ltd
      • Aridis Pharmaceuticals LLC
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aridis Pharmaceuticals LLC
      • Artificial Cell Technologies Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Artificial Cell Technologies Inc
      • AstraZeneca Plc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by AstraZeneca Plc
      • Bavarian Nordic A/S
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Bavarian Nordic A/S
      • Celltrion Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Celltrion Inc
      • Curevac AG
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Curevac AG
      • DBV Technologies SA
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by DBV Technologies SA
      • Enanta Pharmaceuticals Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enanta Pharmaceuticals Inc
      • Evec Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Evec Inc
      • F. Hoffmann-La Roche Ltd
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by F. Hoffmann-La Roche Ltd
      • Gene Techno Science Co Ltd
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gene Techno Science Co Ltd
      • GenVec Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by GenVec Inc
      • Gilead Sciences Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gilead Sciences Inc
      • GlaxoSmithKline Plc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by GlaxoSmithKline Plc
      • iBio Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by iBio Inc
      • Immunovaccine Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunovaccine Inc
      • Immunwork Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunwork Inc
      • Inovio Pharmaceuticals Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inovio Pharmaceuticals Inc
      • Johnson & Johnson
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Johnson & Johnson
      • Karyopharm Therapeutics Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Karyopharm Therapeutics Inc
      • Kineta Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Kineta Inc
      • mAbxience SA
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by mAbxience SA
      • MedImmune LLC
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by MedImmune LLC
      • Medivir AB
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Medivir AB
      • Mymetics Corp
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mymetics Corp
      • NanoBio Corp
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by NanoBio Corp
      • Navigen Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Navigen Inc
      • Novavax Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Novavax Inc
      • Phoenix Biotechnology Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Phoenix Biotechnology Inc
      • Profectus BioSciences Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Profectus BioSciences Inc
      • Pulmocide Ltd
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pulmocide Ltd
      • ReViral Ltd
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by ReViral Ltd
      • Romark Laboratories LC
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Romark Laboratories LC
      • Takeda Pharmaceutical Co Ltd
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Takeda Pharmaceutical Co Ltd
      • TechnoVax Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by TechnoVax Inc
      • Themis Bioscience GmbH
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Themis Bioscience GmbH
      • Vault Pharma Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vault Pharma Inc
      • Vaxart Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxart Inc
      • Virometix AG
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Virometix AG
      • Visterra Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by Visterra Inc
      • VLP Biotech Inc
        • Table Respiratory Syncytial Virus (RSV) Infections – Pipeline by VLP Biotech Inc
    • Human Parainfluenza Virus 3 Infections
      • Table Human Parainfluenza Virus 3 Infections – Pipeline by 3-V Biosciences Inc
      • Amarillo Biosciences Inc
        • Table Human Parainfluenza Virus 3 Infections – Pipeline by Amarillo Biosciences Inc
      • Ansun Biopharma Inc
        • Table Human Parainfluenza Virus 3 Infections – Pipeline by Ansun Biopharma Inc
      • Moderna Therapeutics Inc
        • Table Human Parainfluenza Virus 3 Infections – Pipeline by Moderna Therapeutics Inc
  • Dormant Projects
    • Respiratory Syncytial Virus (RSV) Infections
      • Table Respiratory Syncytial Virus (RSV) Infections – Dormant Projects
    • Human Parainfluenza Virus 3 Infections
      • Table Human Parainfluenza Virus 3 Infections – Dormant Projects
  • Discontinued Products
    • Respiratory Syncytial Virus (RSV) Infections
      • Table Respiratory Syncytial Virus (RSV) Infections – Discontinued Products
    • Human Parainfluenza Virus 3 Infections
      • Table Human Parainfluenza Virus 3 Infections – Discontinued Products
  • Product Development Milestones
    • Respiratory Syncytial Virus (RSV) Infections
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report